Nelli® is CE-marked as a class I medical device according to Directive 93/42/EEC.
Nelli® is commercially available in the European Union.
Nelli® has been granted Breakthrough Device Designation by
the US FDA.
Nelli® in the United States is an investigational device, limited by Federal law to investigational use.
See
Fast and accurate seizure detection at home* and in the hospital
Learn
Objective and easy-to-use data provided by AI and reviewed by a human expert
Improve
Better diagnostics and improved follow upNelli® analyzes audio/video recordings to identify events indicative of motor seizures.
Video and audio recordings of the patient are captured via a Personal Recording Unit (PRU) with camera and microphone.
Nelli® consists of an electronic service for patient data analysis and a web-based dashboard for viewing of the results. Relevant motions and sounds are analyzed by machine learning algorithms resulting in an interactive report to be reviewed by the physician.
Research supports accuracy of seizure detection
In a study comparing Nelli® to VEEG in 230 patients
-
88%
Sensitivity for all motor seizures1
-
95.2%
Sensitivity for convulsive seizures1
-
6.48
False detection rate per hour for all motor seizures 1
1 Rai P. et al. Automated analysis and detection of epileptic seizures in video recordings using Artificial Intelligence. Frontiers in Neuroinformatics (2024).
In a study with 104 patients monitored for an average of 29 days, using Nelli® led to
-
>86%
Clinical decisions2
-
83
Differential diagnosis of all patients with recorded epidoses2
-
68%
Therapeutic interventions or adjustments2
2 Basnyat P. et al. Clinical utility of a video/audio-based epilepsy monitoring system Nelli. Epilepsy & Behavior (2022).
